You are on page 1of 28

MCQ 11 : 1/2557

Disclaimer :

1/2557
120 3
5 ( choice 555++)
1 555++ ( ** )
(
)


Everything under the sun

......

************************************************
% % 1/2557
8 2557 09.00 - 12.00 . MCQ 11
1
10

penicillins
1. %
%
(1)
(2)
(3)
(4)
(5)
Note : MCQ1/2554

2. %

(1)
(2)
(3)
(4)
(5)
3. %
%
(1) Rubbing alcohol
(2) Chlorhexidine
(3) Irrigated normal saline solution
(4) Acetic acid
(5) Povidone iodine

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 2


4. %**
(1) Silver sulfadiazine cream
(2) Oxytetracycline ointment
(3) Chloramphenicol gel
(4) Bacitracin cream
(5) Neomycin powder
5. % %


(1) Streptococcus pyogenes
(2) Streptococcus pneumoniae
(3) Staphylococcus aureus
(4) Staphylococcus epidemidis
(5) Escherichia coli
6.
(1) Doxycycline
(2) Chloramphenicol
(3) Sulfacillin
(4) Dicloxacillin
(5) Clindamycin
7. %
MRSA positive

(1) Bacitracin
(2) Polymyxin
(3) Neomycin
(4) Mupirocin
(5) Chloramphenicol
8. Fanconi
syndrome

(1)

(3)

(4)

(5)
2
65

Metformin (500) 1x3 pc
Simvastatin (20) 1x1 pc
Enalapril (10) 1x1 pc
BP 132/82 mmHg, FBS
129 mg/dL, HbA1C = 7.9%
9.
(1) Glipizide (5) 1x2 ac
(2) Aspirin (81) 1x1 pc
(3) Amlodipine (5) 1x1 pc
(4) Glimepiride (1) 1x2 pc
(5) Clopidogrel (75) 1x1 pc
10. American
Diabetic Association 2013 %
HbA1C
(1) 6.0 %
(2) 6.5 %
(3) 7.0 %
(4) 7.5 %
(5) 8.0 %

(2)
Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 3




Na 140 mEq/L, Cl 108 mEq/L, K 4.2
mEq/L HCO3- 10 mEq/L
11. % %
(1) Metformin
(2) Simvastatin
(3) Enalapril
(4) glucose
(5) sodium bicarbonate
12. Insulin IV
diabetic ketoacidosis
(1) NPH insulin
(2) Regular insulin
(3) Insulin Glargine
(4) Insulin Lispro
(5) Insulin Detemir
13. Insulin

(1) Protamine sulfate
(2) Calcium carbonate
(3) Triethanolamine
(4) Sodium chloride
(5) Dextrose
14.
(1) Glipizide :
: hypoglycemia
(2) Metformin : hypoglycemia
: 12
(3) Pioglitazone :
: hypoglycemia
(4) Acarbose : HbA1C metformin
:
(5) Insulin :
: hypoglycemia

15.
sulfonamides

(1)

(2)

(3)

(4)

(5)
16. NPH insulin 45 unit
30 unit
4 insulin
vial (NPH insulin
100 unit/mL 1 vial 10 mL)
(1) 1
(2) 2
(3) 3
(4) 4
(5) 5
17. %
(1)
(2)
(3)
(4)
(5)

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 4


18. % A
%
% A %

(6) 1A 301/50
(7) 2D 11/51
(8) 3G 32/52
(9) 2G 18/53
(10) 1J 102/54
19. NPH Insulin
(1)
(2)
(3)

(4)
(5)

21. > paclitaxel


(1) Alkylating agent
(2) Topoisomerase inhibitor
(3) Mitotic inhibitor
(4) Antimetabolite
(5) Vascular growth factor receptor antagonist
22. cyclophosphamide

(1) cystitis
(2) dose-related toxicity
(3) = acrolein
(4) extravasation hyaluronidase
antidote
(5) mesna uroprotective

23. anticipatory nausea and


3
vomiting

(1) Dexamethasone

(2) Ondansetron
AC-Paclitaxel-Trastuzumab Regimen
(3) Aprepitant
Doxorubicin: I.V.: 60 mg/m2 day 1
(4) Lorazepam
Cyclophosphamide: I.V.: 600 mg/m2 day 1
(5) Metoclopramide
Repeat cycle every 21 days for 4 cycles, followed by
24.
Paclitaxel: I.V.: 175 mg/m2 day 1
(1)
Trastuzumab : I.V.: 4 mg/kg (loading dose) day
(2)
1 (cycle 1 only) followed by I.V.: 2 mg/kg/day days 8 and
(3)
15 (cycle 1) then I.V.: 2 mg/kg/day days 1, 8, and 15
(4)
(cycles 2, 3, and 4)
(5)
Repeat cycle every 21 days for 4 cycles followed
by Trastuzumab: I.V.: 2 mg/kg weekly for 40 weeks
25.
doxorubicin liposomal preparation
20. Extravasation doxorubicin
(1) =
antidote
(2) photo-oxidation
(1) Hyaluronidase
(3) hydrolysis
(2) Dimethyl sulfoxide
(4)
(3) Mesna
(5)
(4) Dexrazoxane
(5) Leucovorin
Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 5


26. lipophilic
liposomal preparation liposome
(1) liposome
(2) lipid bilayer liposome
(3) phospholipid
(4) liposome
(5) liposome
4
60
Non-ST Elevatrion Myocardial infarction
Simvastatin (40) 1x1 PO pc
Enalapril (10) 1x1 PO pc
Aspirin (81) 1x1 PO pc
Clopidogrel (75) 1x1 PO pc
Amlodipine (20) 1x1 PO pc
Isosorbide dinitrate 1 tab SL prn
27. %
myocardial infarction
(1) Simvastatin
(2) Enalapril
(3) Aspirin
(4) Clopidogrel
(5) Amlodipine
28. oral antiplatelet
(1) 2
(2) 1
(3) 3
(4) 6
(5) 1
29.

(1) Sucralfate
(2) Lansoprazole
(3) Omeprazole
(4) Esomeprazole
(5) Alum milk

30. %
LDL 102 mg/dL, HDL 45 mg/dL, TG 500 mg/dL,
Total cholesterol 220 mg/dL
> simvastatin
(1) Gemfibrozil
(2) Nicotinic acid
(3) Fish oil
(4) Cholestyramin
(5) Ezetimibe
31.
%
(1) simvastatin enalapril
(2) simvastatin amlodipine
(3) simvastatin aspirin
(4) simvastatin clopidogrel
(5) simvastatin isosorbide
dintrate
32. % >
(1) Simvastatin
(2) Clopidogrel
(3) Isosorbide dinitrate
(4) Aspirin
(5) Amlodipine
33.
paracetamol
(1) Celecoxib (200) 1 cap bid pc
(2) Ibuprofen (400) 2 tab tid pc
(3) Naproxen (250) 1 tab bid pc
(4) Aspirin (325) 1 tab tid pc
(5) Mefenamic acid (250) 1 cap tid pc

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 6


38. ( diclofenac core tablet)


(1) Dissolution
(2) Disintegration
(3) Hardness
(4) Uniformity of dosage unit
(5) Moisture content
39. Capsaicin cream %
Capsaicin
0.15 g
5
Cream base qs to
100 g
49 75
Cream base
150 BW 138/82
Stearic acid
150

White wax
20
White petrolatum
80
1
Triethanolamine
15


Propylene glycol
80

Purified water
655
Rheumatoid factor 1:80 uric acid 6.2 mg/dL
Emulsifying agent
35. %
(1) Stearic acid
(1)
(2) White wax
(2)
(3) Triethanolamine
(3)
(4) Triethanolamin stearate
(4)
(5) Propylene glycol
(5)
6
36.
52


(1) Celecoxib (200) 1 cap bid pc
2
(2) Tramadol (50) 1 cap qid pc

(3) Naproxen (250) 1 tab bid pc
T-score = - 2.8
(4) Paracetamol (500) 2 tab prn q 6 hr
Perimenopause
(5) Diclofenac (50) 1 tab tid pc

37.
Estradiol valerate 2 mg day 1 - 10
(1)
Estradiol valerate 2 mg + northisterone 2.5 mg
(2)
day 11 - 21
(3)
(4)
(5)
34. 2



(1) Cost description
(2) Cost minimization analysis
(3) Cost benefit analysis
(4) Cost utility analysis
(5) Cost effectiveness analysis

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 7


40. perimenopause %

(1)
(2)
(3)
(4)
(5)
41. % Hormone replacement

(1)
(2)
(3)
(4)
(5)
42. Norethisterone acetate %

(1)
(2)
(3)
(4)
(5)
43.


(1) Estradiol valerate
tibolone
(2) Norethisterone acetate
tibolone
(3) Estradiol valerate
Raloxifene
(4) Norethisterone acetate
Raloxifene
(5) Estradiol valerate
Conjugated estrogen

44. %

(1) Oral conjugated equine estrogen
(2) Micronized progesterone
(3) Conjugated estrogen
Medroxyprogesterone acetate
(4) Medroxyprogesterone acetate
(5) Conjugated equine estradiol cream
sieving analysis medroxyprogesterone acetate 5 %
( 45 - 46)
(1) 0.05 nm
(2) 8.00 nm
(3) 0.70 mcm
(4) 3.50 mcm
(5) 11.5 mcm
45. sieve oxidation

46. sieve angle of
repose
7
35
3
2
(Ventolin)
5
ibuprofen

47. Ventolin

(1) Budesonide MDI
(2) Ipratropium / Fenoterol MDI
(3) Budesonide / formoterol Turbuhaler
(4) Tiotropium bromide HandiHaler
(5) Fluticasone / salmeterol Accuhaler

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 8


48. Seretide Accuhaler
(1)
3 - 4
(2)
(3)
(4)
1
(5)

53. (Propellant)

MDI
(1) Chlorofluorocarbon 114
(2) Hydrofluoroalkane-134a
(3) ???
(4) ???
(5) ???

49. salbutamol
(1)
(2)
(3)
(4)
(5)

54. MDI A (MW 100 g/mol)


B (MW 170 g/mol) propellant
60:40 MDI
A B = 70
55 psig
(1) 42.00 psig
(2) 47.41 psig
(3) 49.47 psig
(4) 54.94 psig
(5) 64.00 psig

50. asthma exacerbation


ibuprofen
(1) Prostaglandins
(2) Thromboxane
(3) Leukotriene
(4) Histamines
(5) Tumor necrosis factor
51. salbutamol MDI

%
(1) solvent ??
(2)
52. salbutamol

(1) 1 - 5 nanometer
(2) 10 - 50 nanometer
(3) 1 - 5 micrometer
(4) 10 - 50 micrometer
(5) > 100 micrometer

55. Budesonide MDI Seretide Accuhaler

(1)
(2)
(3)

(4)
(5)
8
45

1
20 2
alcoholic cirrhosis

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 9


56. (primary prophylaxis)
variceal bleeding
(1) Octreotide
(2) Pantoprazole
(3) Somatostatin
(4) Propranolol
(5) Lactulose
57.

58.

59.

60.

61.
(1)
(2)
(3)
(4) B
(5)

62.
17.00 - 20.00 .
hepatic encephalopathy
% simethicone 1 15.00 .
%

(1) Lorazepam

(2) Flumazenil
simethicone %
(3) Zinc sulfate

(4) Lactulose
(1)
(5) Rifaximin
(2)
Cirrhosis


(3)
(1) Furosemide + amiloride
(4)
(2) Furosemide + spironolactone
(5)
(3) Hydrochlorothiazide + amiloride

(4) Hydrochlorothiazide + Furosemide
63. Simethicone >
(5) Hydrochlorothiazide + spironolactone

Spontaneous
(1)
bacterial peritonitis (SBP) %


(2)
(1) Staphylococcus aureus

(2) Streptococcus pneumoniae
(3)
(3) Krepsiella pneumoniae

(4) Acinetobacter baumannii
(4) capsule body
(5) Streptococcus epidermidis

(5)

(mottling)
Spontaneous bacterial peritonitis (SBP)
(1) Amoxicillin
(2) Cefotaxime
(3) Colistimethate
(4) Clindamycin
(5) Ofloxacin

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 10


9
58 58

Na 142 (135 - 145 mEq/L)
Cl 107 (98 - 110 mEq/L) K 7.5 (3.5 - 5 mEq/L)
HCO3- 18 (24 - 32 mEq/L) Ca 8.2 (8.8 - 10.5 mg/dL)
P 7.1 (2.5 - 4.9 mg/dL) Alb 2.1 (3.5 - 5.5 g/dL)
BUN 32 (7 - 20 mg/dL) Cr 2.5 (0.8 - 1.2 mg/dL)

64. % % (stage)
(1) Stage I
(2) Stage II
(3) Stage III
(4) Stage IV
(5) Stage V
65. potassium
sodium polystyrene sulfonate

(1) Mucillin
(2) Psylium seed
(3) Lactulose
(4) Sorbital
(5) Magnesium hydroxide
66. % (anemia)

(1) Hypochromic microcytic red cell
(2) Hypochromic normocytic red cell
(3) Hyperchromic macrocytic red cell
(4) Hyperchromic normocytic red cell
(5) Normochromic normocytic red cell

67.
Ferrous sulfate (FeSO4)
(1)
(2)
(3)
(4)
(5)

68.
Aluminium hydroxide (Al(OH)3)
Calcium carbonate (CaCO3)
(1)
(2) CaCO3 PO binding capacity Al(OH)3
(3) CaCO3 Al(OH)3
(4) anemia osteomalacia Al(OH)3
(5) soft tissue calcification Al(OH)3
69.
Calcium carbonate %
(1)
(2)

(3)
(4) FeSO4
(5)
doxycycline
70. FeSO4 potassium
permanganate (KMnO4)
(1) Acid-base titration
(2) Non-aqueous acid-base titration
(3) Oxidation-reaction titration
(4) Complexometric titration
(5) Precipitation titration

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 11


71. Chloride Aluminium 74. %
hydroxide USP34
(1)
Chloride <221> Dissolve 1.0 g in 30 mL of 2 N nitric
(2)
acid, heat to boiling, add water to make 100 mL, and
(3)
filter: a 5.0-mL portion of the filtrate, diluted with an
(4)
equal volume of water, shows no more chloride than
(5)
corresponds to 0.60 mL of 0.020 N hydrochloric acid
Chloride 0.85% 75. %
Aluminium hydroxide batch
(1) Thiamine
%
(2) Riboflavin
(1) Reject Chloride
(3) Pyridoxine
0.70%
(4) Ascorbic acid
(2) Reject Chloride
(5) Mecobalamine
0.75%
76. % parkinsonism
(3) Reject Chloride
(1) Risperidone
0.80%
(2) Haloperidol
(4) Reject Chloride
(3) Clozapine
0.85%
(4) Trihexyphenedyl
(5) Reject Chloride
(5) Ziprasidone
0.90%
77. 5 %
%
10
levodopa/benserzide 1 - 2
62
motor fluctuation %
Parkinsons disease levodopa/benserzide
**
(250/125) 1 x 3 pc
(1) levodopa/benserzide
72. Parkinsons disease
(2) selegiline
(1) Mesolimbic tract
(3) entacarpone
(2) Mesocortical tract
(4) Pramipexole
(3) Nigrostriatal tract
(5) Benztropine
(4) Tuberloinfundibular tract
(5) Vestibulospinal tract
73. Parkinsons disease
(1) Hypertension
(2) Resting tremor
(3) Impaired balance
(4) Slowness of movement
(5) Stiffness to limb movement
Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 12


11
10 Rheumatic heart
disease
amoxicillin
endocarditis
15
-
penicillin V 3
78. %
(1) Anaphylaxis
(2) Angioedema
(3) Urticaria
(4) Septic shock
(5) Red man syndrome
79.
(1) Type I
(2) Type II
(3) Type III
(4) Type IV
(5) Type V
80. %
(1) Chlorpheniramine maleate
(2) Dexamethasone
(3) Ranitidine
(4) Epinephrine
(5) Paracetamol

82. % 30
Epinephrine % 100
mcg/mL IV 6 mL/hr %
Epinephrine mcg/kg/min
(1) 0.33 mcg/kg/min
(2) 0.46 mcg/kg/min
(3) 0.67 mcg/kg/min
(4) 1.00 mcg/kg/min
(5) 2.78 mcg/kg/min

83. Cost
effectiveness analysis 5


(1) A 120 80%
(2) B 110 70%
(3) A 125 85%
(4) A 130 80%
(5) A 110 75%
84. 8.4
0.8
(1) 0.96
(2) 0.80
(3) 0.67
(4) 0.56
(5) 0.48

81. Epinephrine 100


mcg/mL
1 mg/mL vial 1 mL
(1) 1 vial NSS 10 mL
(2) 1 vial NSS 9 mL
(3) 1 vial NSS 100 mL
(4) 1 vial NSS 99 mL
(5) 1 vial NSS
100 mL
Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 11 | 1/2557 | Page 13


85. % (
)

(1)
(2)
(3)
(4)
(5)

86. Incremental
Cost-Effectiveness Ratio B
A
QALY


A
12500
0.82
B
15300
0.90
2800
0.08

(1) 1.09
(2) 1.22
(3) 224
multi-way sensitivity analysis
(4) 17,000
Utility of HSCT patients
(5) 35,000
Utility of BT-ICT patients ICER
Discount rate Direct-on
medical cost of HSCT ICER
Age coefficient
ICER
Utility of BT-ICT patients
ICER

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 : 1/2557
Disclaimer :

1/2557
120 3
5 ( choice 555++)
1 555++ ( ** )
(
)


Everything under the sun

......

************************************************
% % 1/2557
9 2557 09.00 - 12.00 . MCQ 12
1
56 Chronic
kidney disease


1 3 paracetamol
loratadine

Amoxicillin (500) 1 cap tid
#20
Ibuprofen (400) 1 tab tid
#20
Phenylephrine + CPM 1 tab prn #10
1. %
(1) Loratadine
(2) Amoxicillin
(3) Ibuprofen
(4) Phenylephrine
(5) Chlorpheniramine maleate

2. %
pharyngitis
(1) Staphylococcus aureus
(2) Streptococcus pyogenes
(3) Streptococcus epidermidis
(4) Streptococcus pneumoniae
(5) Haemophilus influenzae

communityacquired pneumonia

Ceftazidime 2 g IV OD
Clarithromycin 500 mg MR

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 15


3. % Community-acquired
pneumonia %
(1) Acinetobacter baumannii
(2) Streptococcus pneumoniae
(3) Pseudomonas aeruginosa
(4) Staphylococcus aureus
(5) Burkholderia pseudomalii
4. %

(1) Ceftazidime ceftriaxone
(2) Ceftazidime meropenem
(3) Clarithromycin ciprofloxacin
(4) Clarithromycin 1 x 2
(5)
5. % Krebseilla pneumoniae
ESBL positive
(1)
(2) piperacillin/salbactam
(3) cefoperazone/salbactam
(4) amoxicillin/clavulanate
(5) imipenem/cilastin
6. Amoxicillin

(1)
(2)
(3)
(4)
(5)

A
B
C
D
E

C
E

7. %
bleeding
A

B
E

C
D

(1)
(2)
(3)
(4)
(5)

A
B
C
D
E

8.
(1)
(2)
(3)
(4)
(5)


pseudoephedrine
pseudoephedirine

9.
(1) <
2
(2) < 2

(3) <
2
(4)
(5)

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 16


10.
(1) <
2
(2) < 2

(3) <
2
(4)
(5)

2
21



11. %
(1) Bacterial conjunctivitis
(2) Viral conjunctivitis
(3) Allergic conjunctivitis
(4) Stye ( )
(5) Cataract ()
12. Chloramphenicol eye drop

(1)

(2)

(3) 1


(4)
(5) 3

13. chloramphenicol ointment



(1) Chloramphenicol
(2) Chloramphenicol
(3) Chloramphenicol

(4) Chloramphenicol
(5) ???
14. chloramphenicol

(1)
(2)
(3)
(4)
(5)

Amide hydrolysis
???
???
???
???

contact lens

contact lens
15. % %
contact lens
(1) Staphylococcus aureus
(2) Pseudomonas aeruginosa
(3) Escherichia coli
(4) Krebseilla pneumoniae
(5) Haemophilus influenzae
16. 15. **

combination antibiotic eye drops antibiotics
eye drop ophthalmic decongestant/antihistamines
** ceftazidime ED + gentamicin ED
**

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 17


3
50 48
1
5 3
acid fast bacilli staining
AFB 3+ pulmonary tuberculosis

pulmonary tuberculosis 8
6
17. %%
(1) 2HRZE / 4HR
(2) 2HRZES / 1HRZE / 5HRE
(3) 2SHRE / 6HR
(4) 2SHE / 10HE
(5) 2SEO / 16-22EO
18. hyperuricemia

(1) Isoniazid
(2) Rifampicin
(3) Pyrazinamide
(4) Ethambutol
(5) Streptomycin
19. chronic
kidney disease
(1) Isoniazid
(2) Rifampicin
(3) Pyrazinamide
(4) Ethambutol
(5) Streptomycin
20.
(1) 2RZE / 10RE
(2) 2SHE / 10HE
(3) 2HRE / 7HR
(4) 2SHRE / 6HR
(5) 18-24SEO

21. specific rotation


(1)

(2)

(3)

(4)

(5)
22. Pyrazinamide tablet
pyrazinamide %

(1) Sodium starch glycolate


(2) Croscarmellose sodium
(3) Colloidal silicon dioxide
(4) Magnesium stearate
(5) Sodium lauryl sulfate
23. BCG
%
(1) Killed-vaccine
(2) Immunoglobulin
(3) Toxoid
(4) Lived-attenuated vaccine
(5) Subunit vaccine

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 18


24. 26. %
%

(1) Losartan
%
(2) Metoprolol

(3) Hydrochlorothiazide
(1)
(4) Amlodipine

(2)
(5) Spironolactone

27. %
(3)


(1) Gemfibrozil

(2) Nicotinic acid


(4)
(3) Fenofibrate

(4) Cholestyramine
(5)
(5) Ezetimibe
4
61

Simvastatin 10 mg hs
Enalapril 5 mg OD
Allopurinol 300 mg OD

152/92 mmHg
Triglyceride 500 mg/dL, LDL-cholesterol 90 mg/dL
HDL-cholesterol 45 mg/dL
25. %

(1) 150/90 mmHg
(2) 140/90 mmHg
(3) 140/80 mmHg
(4) 135/85 mmHg
(5) 130/80 mmHg

28.
ACEIs Beta-blockers
myocardial infarction

(1) Case-control study
(2) Case-report study
(3) Cohort study
(4) Randomized control trial
(5) Retrospective study
29. Enalapril

(1) Foil strips


(2) Blisters
(3) Sachets
(4) Glass vial
(5) Glass ampoule

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 19


5
52 FBS 128
mg/dL, HbA1C 7.4% 2
Glipizide 5 mg 1 x 3 ac Metformin 850 mg 1 x 3 pc
30. %
(1)
(2) Acabose 1 x 2 ac
(3) glipizide 2 x 2 ac
(4) Metformin 2 x 2 pc
(5) Insulin
31.
SrCr 1.8 mg/dL

(1)
(2) Glipizide
(3) Metformin
(4) Metformin
(5) Glipizide
32. Chronic Kidney
Disease Insulin +
(1) Glipizide
(2) Gliclazide
(3) Glibenclamide
(4) Acarbose
(5) Pioglitazone
33. Insulin
Insulin liposomal system
liposome
(1)
phospholipid
(2)
(3)

(4)
(5)

34.
second generation sulfonylurea
C

A
(1)
(2)
(3)
(4)
(5)

A
B
C
D
E

35. Metformin
(1) GLUT-2
(2) AMP-activated protein kinase (AMPK)
(3) Sulfonylurea receptor
(4) peroxisome proliferator-activated receptor
gamma (PPAR-)
(5) Dipeptidyl peptidase-4
36. %

%

(1)

(2)

(3)

(4)

(5)

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 20


39.
%
(1)
estrogen
37.
estrogen

(2)
(1)
estrogen
(2)
estrogen
(3)
(3)
(4)
progestin
(5)
progestin
38.
(4)
(
progestin
EE )
progestin
(1) 1
(5)

progestin

progestin
(2) 2 1
1 40. %

B
A

(3) 3


C
(4) 2
(1) Estrogen
1
(2) progesterone

(3) A < anti-androgen

(4) B ethyl <


(5) 2 3
androgen methyl

(5) C <
6
26

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 21


41. A Anti-androgen

(1)

(2)

(3)

(4)

(5)
42.

(1)
(2)
(3)
(4)
(5)
43. %
clotrimazole vaginal tablet
co- trimoxazole tablet %

(1)

(2)
<

(3)

(4)


(5)

7
51

42 161
1

(Bone mineral density) T-score -1.8

Calcium carbonate (1000 mg) 1 x 2 pc


Alendronate (5 mg) once weekly on Saturday
Vitamin D3 (1000 IU) OD
44. %
%
(1)
(2)
(3)
(4)
(5)
45. Calcium carbonate 2 g elemental calcium
(1) 200 mg
(2) 400 mg
(3) 500 mg
(4) 800 mg
(5) 1000 mg
46. Calcium carbonate
(1) Azithromycin
(2) Dicloxacillin
(3) Clindamycin
(4) Cephalexin
(5) Norfloxacin

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 22


47.
Alendronate
(1)
(2)
(3)

(4)
(5)
48. alendronate %
*

A
B

(1)
(2)
(3)
(4)
(5)

Glucuronidation A
Glucuronidation B
Sulfation A
Deamination C

49. A
(1) 1,25-dihydroxycholecalciferol
(2) 1-hydroxycholecalciferol
(3) 25-hydroxycholecalciferol
(4) Cholecalciferol
(5) Calcifediol
50.
(1) Orlistat
(2) Kalimate
(3) Norfloxacin
(4) Tetracycline
(5) Sevelamer

51. A
(1) Plain-compressed tablets
(2) Chewable tablets
(3) Effervescent tablets
(4) Enteric-coated tablets
(5) Film-coated tablets
52. A
B Hazard ratio
A 0.80
B 95% 0.75 1.14 A
...... ..
95% CI 1 sig
A
8
Anxiety + insomnia
pharmacokinetics/dynamics
Fluoxetine, zolpidem, alprazolam 3 4 / K-type
555+++
53. %

(1) Alprazolam
(2) Lorazepam
(3) Diazepam
(4) Chlordizepoxide
(5) Chlorazepate
54. Alprazolam
(1)
(2)
(3) <

(4) <
(5)

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 23


55. Fluoxetine metabolized
norfluoxetine
A

(1)
(2)
(3)
(4)
(5)

A
B
C
D
E

56. Fluoxetine HPLC


%
stationary phase ::: octadecyl carbon chain (C18) bonded silica column
Mobile phase ::: Methanol : water = 60 : 40
retention time = 6.2 peak
tail = 3.25
% mobile phase
(1) methanol + acetonitrile
(2) methanol + phosphate buffer pH 11.8
(3) methanol + acetate buffer pH 5
(4) methanol + . buffer pH 11.8
(5) ...

9
23
3

57. %

(1) Clostidium botulinum
(2) Vibrio cholerae
(3) Salmonella typhi
(4) Shigella dysenteriae
(5) Entamoeba histolytica
58. ORS
(1) Norfloxacin + Paracetamol
(2) Doxycycline + Activated charcoal
(3) Metronidazole + Loperamide
(4) Tinidazole + Activated charcoal
(5) Clindamycin + Kaolin/pectin
59. Loperamide
(1) Diarrhea
(2) Constipation
(3) Orthostatic hypotension
(4) Tachycardia
(5) Blurred vision
60. ORS %
sodium glucose
(1) Sodium 45 mEq, glucose 60 mEq
(2) Sodium 75 mEq, glucose 60 mEq
(3) Sodium 75 mEq, glucose 90 mEq
(4) Sodium 90 mEq, glucose 90 mEq
(5) Sodium 90 mEq, glucose 120 mEq

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 24


61. A activated charcoal
(1) Absorbent
(2) Adsorbent
(3) Decrease gut motility
(4) Prebiotics
(5) Probiotics
62. Kaolin & pectin suspension
%
(1) CMC
(2) ... ...
63. Kaolin & pectin suspension
thixotropic
(1) SCMC
(2) Veegum
(3) ...
64. (Activated charcoal) 10

(1)
(2)

(3)

(4)
(5)

65. (raw material) activated


charcoal
(1) Active ingredient
(2) Specific rotation
(3) Loss on drying
(4) Identification
(5) Contamination

10
26


66. %

(1) Mild comedonal acne
(2) Mild papulopustular acne
(3) Moderate papulopustular acne
(4) Moderate nodular acne
(5) Severe acne conglobata
67.
(1) Topical tretinoin
(2) Clindamycin gel
(3) Oral doxycycline
(4) Oral isotretinoin
(5) Combination contraceptive pills
68. %
%

(1) Mild comedonal acne
(2) Mild papulopustular acne
(3) Moderate papulopustular acne
(4) Moderate nodular acne
(5) Severe acne conglobata
69. 68.
(1) Oral tetracycline + topical tretinoin
(2) Topical tretinoin + benzoyl peroxide
(3) Oral isotretinoin + Topical retinoid
(4) Combination contraceptive pills + benzoyl peroxide
(5) Topical tretinoin + clindamycin gel

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 25


70. %
(1) Staphylococcus aureus
(2) Malassezia furfur
(3) Propionibacterium acnes
(4) Streptococcus epidemides
(5) Microsporum gypseum
71. Tretinoin cream oral isotretinoin

(1) ,

(2) ,

(3) ,
(4) ,
(5) ,
72. oral
isotretinoin
(1)

(2) 1

(3) 1
1
(4)

(5)

73. isotretinoin soft gelatin
capsules vegetable oil isotretinoin

(1) Fillers
(2) Co-solvents
(3) Antioxidants
(4) Disintegrants
(5) Binders

74. clindamycin gel



(1)
(2)

(3)

(4)

(5)

75. Isotretinoin
%

(1)
(2)
(3)
(4)
(5)

UV-visible Spectroscopy
Atomic Absorption Spectrophotometry
Mass Spectroscopy
Nuclear Magnetic Resonance Spectroscopy
Infrared Spectroscopy

11
29 50
Thalassemia
76. Thalassemia
(1) hemoglobin
globin
(2) hemoglobin

(3)
methemoglobin
(4)

(5)
12

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 26


77. Thalassemia
(1) Peripheral blood smear
(2) Bone marrow biopsy
(3) ...
78. %
Thallassemia

(1) 0%
(2) 25%
(3) 50%
(4) 75%
(5) 100%
79. Desferrioxamine 40
mg/kg/day Desferrioxamine
250 mg/mL IV infusion
10 drip rate (
2 g/vial)
(1) 50 mg/hr
(2) 100 mg/hr
(3) 150 mg/hr
(4) 200 mg/hr
(5) 250 mg/hr
80. Desferrioxamine % %

(1) pH
(2) Sterility
(3) Pyrogen
(4) Particulate matter
(5) Osmolarity of solution

81. Desferrioxamine

(1)
(2)
(3)
(4)
(5)

A
B
C
D
E

82. Desferrioxamine

%
(1) Desferrioxamine

(2)
Desferrioxamine

(3)
(4) ... ...
12
10


83. %
(1)
(2) povidone iodine
(3) rubbing alcohol
(4)
(5)

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 27


84.
(1) immunoglobulin
(2) immunoglobulin
7
(3) immunoglobulin

(4)
(5)
(intradermal) 0, 3, 7, 14 30
85. % 3 5

(1)
(2) 1 ( 0)
(3) 2 0 3
(4) 3 0, 3 7
(5)

86.


% 2
1
(1) 1
(2) 2
(3) 2
1
(4) 2 1

(5) 2 1

1
87.
(pre-exposure immunization)

(1) 1
(2) 2 0 3
(3) 2 0 7
(4) 3 0, 3 7
(5) 3 0, 7 28

88. Vaccine
(1) .... .....
89. A
AA
(1) A AA

(2) A AA

(3) A AA

(4) ... ...


90. AA


(
Relative risk) ()

4
98

43
61

(1) (4/43) / (98/61)
(2) (4/47) / (98/159)
(3) (4/61) / (43/98)
(4) (4/98) / (43/61)
(5) (4/102) / (43/104)
91.
% (Intramuscular)
(1)
(Adjuvant)
(2) <
(Intravenous)
(3) Bioavailability 100%
(4)

Final version | Maximum2017 Rx30 | Prince of Songkla University

MCQ 12 | 1/2557 | Page 28

...
92. % isolator
93. Hazard ratio 95% confidence interval
94.

(1)
(2)
(3)
(4) (
)
(5) ICER

96. Capping
(1) magnesium stearate
(2)
(3)
(4) polyvinyl acetate
(5)
97. dry granulation
compressability index = 33 angle of repose =
45.8O
(1) Magnesium stearate
(2) Colloidal silicon dioxide
(3)

95. %

(1) Disintegration
(2) Dissolution
(3) Hardness
(4) Identification
(5) Uniformity of dosage unit

Final version | Maximum2017 Rx30 | Prince of Songkla University